2023
Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal Of Dermatology 2023, 189: 339-341. PMID: 37140007, PMCID: PMC10947518, DOI: 10.1093/bjd/ljad149.Peer-Reviewed Original ResearchConceptsIL-13 expressionBullous pemphigoidImmune-related adverse eventsComplete disease clearancePromising new therapyNovel therapeutic approachesDisease clearanceAdverse eventsTumor immunityTherapeutic approachesNew therapiesConventional treatmentPemphigoidInterleukinTreatmentPatientsExpressionTherapyImmunityClearance
2021
30 Rituximab
Gehlhausen J, Heffernan M, Tomayko M. 30 Rituximab. 2021, 330-338.e3. DOI: 10.1016/b978-0-323-61211-1.00030-9.ChaptersMucous membrane pemphigoidEpidermolysis bullosa acquisitaMechanism of actionCutaneous lupusHost diseaseBullous pemphigoidPemphigus vulgarisPemphigus foliaceusRituximabB cellsUS FoodDrug AdministrationDermatologic usesMonoclonal antibodiesPemphigoidTreatmentCD20AcquisitaLupusFoliaceusGraftDiseaseAdministrationAntibodiesPharmacology